Advanz Pharma (OTCMKTS:CXRXF) Sets New 1-Year Low at $12.60

Advanz Pharma Corp (OTCMKTS:CXRXF)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as $12.60 and last traded at $12.60, with a volume of 1865 shares traded. The stock had previously closed at $13.29.

A number of brokerages have commented on CXRXF. ValuEngine raised shares of Advanz Pharma from a “sell” rating to a “hold” rating in a report on Thursday. Zacks Investment Research downgraded shares of Advanz Pharma from a “buy” rating to a “hold” rating in a research report on Monday, July 15th.

The company has a current ratio of 2.01, a quick ratio of 1.71 and a debt-to-equity ratio of 6.47. The business’s 50-day moving average price is $15.32.

Advanz Pharma (OTCMKTS:CXRXF) last released its earnings results on Friday, May 10th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $135.64 million for the quarter. On average, equities research analysts forecast that Advanz Pharma Corp will post -1.58 EPS for the current year.

About Advanz Pharma (OTCMKTS:CXRXF)

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Featured Story: Capital gains and your 401(k) or IRA

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.